Advertisement

Supportive Care in Cancer

, Volume 16, Issue 4, pp 387–392 | Cite as

Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis

  • Nicolas PenelEmail author
  • Sylvain Dewas
  • Philippe Doutrelant
  • Stéphanie Clisant
  • Yazdan Yazdanpanah
  • Antoine Adenis
Original Article

Abstract

Background

Cancer-associated hypercalcemia (CAH) is the most frequent metabolic disorder in cancer patients. We retrospectively reviewed the outcome and prognostic factors for patients with CAH being treated with standard intravenous disphosphonates.

Materials and methods

Two hundred sixty patients were reviewed. Overall survival and prognostic factors were analyzed. Relative risks (RR) for early death (within 60 days) were assessed (Fischer exact test and logistic regression model).

Results

Median survival was 64 days (range, 12–1,955+). Multivariate analysis identified the following factors as poor survival predictors: serum corrected calcium >2.83 mmol/l [hazard ratio (HR) = HR 2.21], albuminemia <35.5 (HR 2.41), squamous cell carcinoma (HR 2.64), bone metastasis (HR 1.44), and liver metastasis (HR 2..22). One hundred twenty-one patients died within 60 days. For those patients, the logistic regression model identified four independent predicting factors for early death: calcemia >2.83 mmol/l (RR 5.07), hypoalbuminemia (RR 7.42), liver metastasis (RR 4.34), and squamous cell carcinomas (RR 2.21).

Discussion

Despite intravenous diphosphonate, CAH is still associated with poor outcome. Simple bedside parameters may estimate the risk of early deaths.

Keywords

Cancer Diphosphonates Hypercalcemia Supportive care Prognosis 

References

  1. 1.
    Besarb A, Caro JF (1978) Mechanisms of hypercalcemia in malignancy. Cancer 41:2276–2285CrossRefGoogle Scholar
  2. 2.
    Brada M, Rowley M, Grant DJ, Ashley S, Powles TJ (1990) Hypercalcemia in patients with disseminated breast cancer. Acta Oncol 29:577–580PubMedCrossRefGoogle Scholar
  3. 3.
    Body JJ, Borkowski A, Cleeren A et al (1986) Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 4:1177–1183PubMedGoogle Scholar
  4. 4.
    Nussbaum SR, Younger J, Vandepol CJ et al (1993) Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297–304PubMedCrossRefGoogle Scholar
  5. 5.
    Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of biphosphonates. Cancer 88:2961–2978PubMedCrossRefGoogle Scholar
  6. 6.
    Major P, Lhortolary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy a pooled analysis of two-randomized controlled clinical trials. J Clin Oncol 19:558–567PubMedGoogle Scholar
  7. 7.
    Monno S, Nagata A, Furuta S (1987) Hypercalcemia of cancer in the aerodigestive tract. J Clin Gastroenterol 9:78–82PubMedCrossRefGoogle Scholar
  8. 8.
    Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT (1990) Cancer-associated hypercalcemia morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 112:499–504PubMedGoogle Scholar
  9. 9.
    Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr (2006) Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 12:47–53PubMedCrossRefGoogle Scholar
  10. 10.
    Kristensen B, Ejlersten B, Mouridsen HT, Loft H (1998) Survival in breast cancer patients after the first episode of hypercalcemia. J Intern Med 244:189–198PubMedCrossRefGoogle Scholar
  11. 11.
    Payne RB, Carver ME, Morgan DB (1979) Interpretation of serum total calcium effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 32:56–60PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  13. 13.
    Mantel N (1966) Estimation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170PubMedGoogle Scholar
  14. 14.
    Cox D (1972) Regression models and life tables (with discussion). J R Stat Soc B 34:187–220Google Scholar
  15. 15.
    Chasan SA, Pothel LR, Huben RP (1989) Management and prognostic significance of hypercalcemia in renal cell carcinomas. J Urology 33:167–170CrossRefGoogle Scholar
  16. 16.
    Degardin M, N’Guyen M, Beaurin D et al (1995) Hypercalcémie et carcinomes épidermoides des voies aéro-digestives supérieures. Incidence et pronostic. Bull Cancer 82:975–980PubMedGoogle Scholar
  17. 17.
    Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS (1991) The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol 145:248–250PubMedGoogle Scholar
  18. 18.
    Penel N Berthon C, Everard F et al (2005) Prognosis of hypercalcemia in aerodigestive tract cancers Study of 136 recent cases. Oral Oncology 41:884–889CrossRefGoogle Scholar
  19. 19.
    Wysolmerski JJ, Broadus AE (1994) Hypercalcemia of malignancy: the central role of parathyroid hormone related protein. Ann Rev Med 45:189–200PubMedCrossRefGoogle Scholar
  20. 20.
    Skrabanek P, Mc Partlin J, Powell D (1980) Tumor hypercalcemia and “ectopic” hyperparathyroidism”. Medicine 59:262–282PubMedCrossRefGoogle Scholar
  21. 21.
    Wimalawansa SJ (1994) Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated. with diphosphonate. Cancer 73:2223–2230PubMedCrossRefGoogle Scholar
  22. 22.
    Walls J, Ratcliffe WA, Howell A, Bundred NJ (1994) Response to intravenous biphosphonate therapy in hypercalcemic patients without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 70:169–172PubMedGoogle Scholar
  23. 23.
    Gurney H, Grill V, Martin TJ (1993) Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcemia. Lancet 341:1611–1613PubMedCrossRefGoogle Scholar
  24. 24.
    De Wits S, Cleton FJ (1994) Hypercalcemia in patients with breast cancer: a survival study. J Cancer Res Clin Oncol 120:610–614CrossRefGoogle Scholar
  25. 25.
    Truong NU, deB Edwardes MD, Papavasiliou V, Goltzman D, Kremer R (2003) Parathyroid hormone-related peptide and survival with cancer and hypercalcemia. Am J Med 115:115–121PubMedCrossRefGoogle Scholar
  26. 26.
    Augustson BM, Begum G, Dunn JA et al (2005) Early mortality after diagnosis of multiple myeloma analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukemia Working Party. J Clin Oncol 23:9219–9226PubMedCrossRefGoogle Scholar
  27. 27.
    Ling PJ, A’Hern RP, Hardy JR (1995) Analysis of survival following treatment of tumour-induced hypercalcemia with intravenous pamidronate (APD). Br J Cancer 72:206–209PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Nicolas Penel
    • 1
    • 2
    Email author
  • Sylvain Dewas
    • 1
    • 3
  • Philippe Doutrelant
    • 4
  • Stéphanie Clisant
    • 5
  • Yazdan Yazdanpanah
    • 2
  • Antoine Adenis
    • 6
  1. 1.Département de Cancérologie GénéraleCentre Oscar LambretLilleFrance
  2. 2.Equipe d’Accueil 2694: Santé Publique, Epidémiologie et modélisation des maladies chroniquesUniversité Lille IILilleFrance
  3. 3.Département Universitaire de RadiothérapieCentre Oscar LambretLilleFrance
  4. 4.Laboratoire de BiologieCentre Oscar LambretLilleFrance
  5. 5.Unité de Recherche cliniqueCentre Oscar LambretLilleFrance
  6. 6.Département de Cancérologie Digestive et UrologiqueCentre Oscar LambretLilleFrance

Personalised recommendations